On Feb. 1, biopharmaceutical company Celgene (NASDAQ:CELG) released fourth-quarter earnings for the period ended Dec. 31, 2006.
- Revenues increased by a drastic 84%, driven by an increase in sales of Revlimid and Thalomid and partially offset by a decrease in sales of Alkeran.
- The company was added to the S&P 500 index on Nov. 3, 2006, and subsequently completed a 20-million-share offering that raised $1 billion.
- For 2007, the company expects revenue to increase to $1.3 billion and EPS to double to approximately $1.
- Celgene has a modest two-star rating in CAPS. Think Celgene should be rated higher? Then sign up and make your vote count!
(Figures in millions, except per-share data)
Income Statement Highlights
|
Q4 2006 |
Q4 2005 |
Change | |
|---|---|---|---|
|
Sales |
$275.0 |
$149.3 |
84.1% |
|
Net Profit |
$22.9 |
$3.9 |
483.3% |
|
EPS |
$0.06 |
$0.01 |
500.0% |
|
Diluted Shares |
419.3 |
360.0 |
16.5% |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q4 2006 |
Q4 2005 |
Change* | |
|---|---|---|---|
|
Gross Margin |
87.4% |
82.1% |
5.3 |
|
Operating Margin |
21.7% |
9.7% |
12.0 |
|
Net Margin |
8.3% |
2.6% |
5.7 |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$1,982.2 |
$724.3 |
173.7% |
|
Accounts Rec. |
No Data |
No Data |
No Data |
|
Inventory |
No Data |
No Data |
No Data |
|
Liabilities |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Accounts Payable |
No Data |
No Data |
No Data |
|
Long-Term Debt |
$399 |
$400 |
0% |
Learn the ways of the balance sheet.
Cash Flow Highlights
A statement of cash flows was not provided. Boo!
Find out why Fools always follow the money.
Related Companies:
- Amgen (NASDAQ:AMGN)
- Genzyme (NASDAQ:GENZ)
- OSI Pharmaceuticals (NASDAQ:OSIP)
- Gilead Sciences (NASDAQ:GILD)
- ImClone Systems (NASDAQ:IMCL)
Related Foolishness:
You can check out any of the Fool's newsletters with a 30-day free trial.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
